Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

In this online program, experts discuss how to best use BTK inhibitors to enhance patient care across multiple B-cell malignancies. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium in Orlando, and read expert commentaries on the new data to learn more about how and when to use BTK-targeted regimens for your patients with cancer.
Ian W. Flinn, MD, PhD
John Pagel Headshot
John Pagel, MD, PhD

ClinicalThought

With 2 BTK inhibitors currently approved for various hematologic malignancies, I will discuss the rationale and importance of continuing to develop additional agents in this class and what we hope to achieve.

John Pagel Headshot John Pagel, MD, PhD Released: October 24, 2019

At our recent symposium at the 2019 ASH meeting, my colleagues and I discussed our perspectives on the use of BTK inhibitor therapy for B-cell malignancies. Here I have provided insights into to some of the major themes asked on this topic.

Ian W. Flinn, MD, PhD Released: February 21, 2020

Are you ready to include BTK inhibitor zanubrutinib as a treatment option for patients with MCL in your practice?

John Pagel Headshot John Pagel, MD, PhD Released: March 24, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue